Publications 2023

Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Moe JO, Eide IJZ, Lund-Iversen M, Brustugun OT (2023)
"Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer"
Diagn Pathol, 18 (1), 70
DOI 10.1186/s13000-023-01357-1, PubMed 37237384

Eide IJZ, Nilssen Y, Stensland EM, Brustugun OT (2023)
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway-A Nation-Wide Population Study
Cancers (Basel), 15 (5)
DOI 10.3390/cancers15051505, PubMed 36900294

Publications 2022

Alexeyenko A, Brustugun OT, Eide IJZ, Gencheva R, Kosibaty Z, Lai Y, de Petris L, Tsakonas G, Grundberg O, Franzen B, Viktorsson K, Lewensohn R, Hydbring P, Ekman S (2022)
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Transl Lung Cancer Res, 11 (10), 2064-2078
DOI 10.21037/tlcr-22-236, PubMed 36386450

Eide IJZ, Nilssen Y, Lund-Iversen M, Brustugun OT (2022)
Factors affecting outcome in resected EGFR-mutated lung cancer
Acta Oncol, 61 (6), 749-756
DOI 10.1080/0284186X.2022.2066984, PubMed 35473448

Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Transl Lung Cancer Res, 11 (6), 953-963
DOI 10.21037/tlcr-21-995, PubMed 35832438

Kaźmierczak D, Eide IJZ, Gencheva R, Lai Y, Lewensohn R, Tsakonas G, Grundberg O, de Petris L, McGowan M, Brustugun OT, Ekman S, Hydbring P (2022)
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
Transl Lung Cancer Res, 11 (5), 722-734
DOI 10.21037/tlcr-21-955, PubMed 35693293

Publications 2021

Brustugun OT, Nilssen Y, Eide IJZ (2021)
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study
Acta Oncol, 60 (10), 1250-1256
DOI 10.1080/0284186X.2021.1955971, PubMed 34313510

Eide IJZ, Brustugun OT (2021)
[Lung cancer treated abroad with receptor tyrosine kinase inhibitor]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0147, PubMed 34505490

Eide IJZ, Brustugun OT (2021)
Lung cancer treated with receptor tyrosine kinase inhibits abroad
Tidsskr. Nor. Laegeforen., 141 (12), 1199-1201

Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Acta Oncol, 60 (12), 1565-1571
DOI 10.1080/0284186X.2021.1973092, PubMed 34486915

Publications 2020

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138